Diabetic Vision Loss

About Verseon

Verseon is a private, platform-based biotech company founded in 2002, leveraging its 'Deep Quantum Modeling' and AI technology to engineer novel small molecule drugs. Its pipeline is robust, with 14 candidates across 7 programs, including a clinical-stage program for anticoagulation and several preclinical oncology programs. The company's core thesis is that its physics-first computational platform can systematically discover high-value drug candidates for major diseases with significant unmet need, positioning it as a potential disruptor in drug discovery.

Therapeutic Areas